Spectroscopic urinalysis technology for chronic kidney disease detection
Introducing a cost-effective spectroscopic urinalysis technology designed for early detection of chronic kidney disease. This innovative home kit empowers patients by quantifying disease markers, enhancing early intervention and management.
Overview
Chronic kidney disease (CKD) management can be significantly improved through early detection and patient empowerment. Our innovative solution involves a spectroscopic urinalysis technology that leverages low-cost instrumentation to quantify markers associated with CKD. This home-based kit offers patients a convenient and effective means to monitor their kidney health, facilitating timely interventions and better disease management.
Technical specifications
Our technology utilizes spectroscopic methods to analyze urine samples, providing precise quantification of CKD markers. The instrumentation is designed to be cost-effective, with a total production cost of approximately $300 per unit. The system is complemented by remote software that processes data and delivers accurate results. This affordable solution ensures accessibility and empowers patients with critical health information, enabling proactive health management.
Technology readiness level
Currently, the technology is at TRL 4, indicating that it has been validated in a laboratory setting. Further development and validation in real-world settings are planned as part of a joint venture or collaboration, allowing for refinement and optimization based on user needs and feedback.
About Spectral Platforms
Spectral Platforms is a biotechnology company focused on developing rapid diagnostic solutions for clinical microbiology. The company has created proprietary technology that detects bacterial pathogens by measuring metabolic markers and redox state changes in clinical samples. This approach aims to bypass traditional, time-consuming culture methods, offering diagnostic results for bacteria presence within 30 minutes. By enabling faster identification and antimicrobial susceptibility testing (AST), the platform is designed to provide actionable data for clinicians to initiate effective antibiotic therapy significantly earlier than current standards allow.
This technology is primarily intended for use in triaging patients at risk of sepsis and managing infectious diseases. By providing rapid and reliable results, including AST results for both single and poly-microbial samples, the company seeks to improve patient outcomes and optimize clinical decision-making. Founded in 2010 and based in Duarte, California, Spectral Platforms engages in research and development for the medical diagnostics industry, often working within the healthcare, biotechnology, and life sciences sectors to validate its diagnostic innovations for clinical environments.
delivered to your inbox.